Outlook Therapeutics

OTLK

Biotechnology · Healthcare

Price

$1.39

-0.07 (-4.79%)

Market Cap

$57.2M

Exchange

NASDAQ Capital Market

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Share count rising — dilution

+233.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 7.6M (2021) → 25.5M (2025)

Outlook Therapeutics is a small biotech company focused on developing a drug to treat serious eye diseases. Its main product is ONS-5010 (branded as LYTENAVA), a form of bevacizumab designed to treat wet age-related macular degeneration, a condition that can cause blindness in older adults. The company targets ophthalmologists and their patients, competing in a market already served by established drugs like Eylea and Lucentis.

The company earns revenue by selling its eye injection drug, though it is still in the very early stages of commercialization and currently spends far more money than it brings in — as shown by its deeply negative margins. It operates primarily in the United States and is a very small player in a crowded field dominated by much larger pharmaceutical companies. The biggest risk it faces is gaining meaningful market share against well-entrenched competitors while managing its limited cash runway to fund ongoing operations.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+96.4% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$27.2T/ year

↑ Rising (+65082964% vs prior year)

>1,000% of revenue

106826895.4x the sector average (18%)

Investing heavily in future products and technology

Insider Activity

34.5%ownership

Insiders own a meaningful stake in the company

Cash Runway

~3 months

$8M cash & investments

Short runway — potential dilution ahead through share issuance

Heavy R&D investment

Outlook Therapeutics is putting 1922884117% of revenue into R&D and that number is rising. That's 106826895.4x the sector average.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

-17.2%

Thin — -17.2% gross margin

Operating Margin

-11006.8%

Losing money on operations — -11006.8%

ROCE

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

N/A

Data not available

EPS YoY

N/A

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

Data not available

FCF Margin

-3159.7%

Burning cash (-3159.7%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

N/A

—

Data not available

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial